Barclays analyst Matt Miksic raised the firm’s price target on Abbott to $133 from $132 and keeps an Overweight rating on the shares following the “strong” Q3 report. Abbott’s strong diabetes results raised investor confidence incrementally higher that GLP-1-related pressure on diabetes stocks may finally be bottoming, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABT:
- Early notable gainers among liquid option names on October 18th
- Unusually active option classes on open October 18th
- Abbott sees Q4 EPS $1.17-$1.21, consensus $1.19
- Abbott reports Q3 worldwide Medical Devices sales up 16.6% on reported basis
- Abbott narrows FY23 adjusted EPS view to $4.42-$4.46 from $4.30-$4.50